cenegermin

09/01/2020 - "Cenegermin 0.002% has emerged as a promising treatment for neurotrophic keratitis. "
01/01/2019 - "Preliminary clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis; however, the clinical experience with this drug is still limited. "
11/01/2022 - "To evaluate corneal healing in patients with moderate and severe neurotrophic keratitis (NK) treated with topical rh-NFG (Cenegermin). "
04/01/2020 - "Cenegermin: A Review in Neurotrophic Keratitis."
12/01/2019 - "As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of cenegermin (OXERVATE®, Dompé) to submit evidence for the clinical and cost effectiveness of cenegermin for neurotrophic keratitis (NK). "

02/01/2021 - "Cenegermin was effective in treating NK in an infant with Goldenhar syndrome."
02/01/2021 - "This study aimed to present the efficacy and safety of cenegermin eye drop (Oxervate; Dompè Farmaceutici, Milan, Italy) treatment in a pediatric patient affected by neurotrophic keratopathy (NK) with Goldenhar syndrome. "

01/01/2020 - "Compared to vehicle, cenegermin-treated patients showed statistically significant reductions in lesion size and disease progression rates during masked treatment. "
07/01/2022 - "This report highlights the safety and prolonged effects of cenegermin for the treatment of pediatric iatrogenic neurotrophic keratopathy, as evidenced by the clinical course and IVCM."
04/01/2020 - "The rate of complete corneal healing was generally higher, and that of disease progression was lower, with cenegermin than with vehicle. "
09/01/2022 - "Such deposits: (1) may represent an esthetic issue only as at least in our patient they were not symptom provoking, questionably interfered with the clinical course of the cenegermin therapy and did not require drug cessation, (2) may implicate both contact lenses and high frequency drug application as previously unidentified but formal risk factors for drug precipitate deposit formation, and (3) may act as a time-release medication reservoir enhancing drug delivery and long-term treatment efficacy."

09/01/2020 - "Cenegermin was ceased, after which the lesion resolved, visual acuity improved, and eye pain resolved. "

05/01/2022 - "Cenegermin should be used in combination with conventional therapy for advanced NK, as it is an effective treatment for healing corneal ulcers, improving the corneal surface homeostasis and avoiding surgery."